Bordetella (pertussis) (whooping cough) bacterial respiratory childhood infections

1
Bordetella(pertussis)(whooping cough)
bacterial respiratory childhood infections

• B . Pertussis
• B . parapertussis

2
B .pertussis

• Small gram-negative bacilli
• Most fastidious
• Culture media containing charcoal
• bordet-Gengou medium
• Charcoal blood agar
• Strict aerobe
• Slow growth (3 days)
• 3 major agglutinogens ( attachment )
• (1, 2 and 3)
• detected by specific antiserum
• Role in immunity
• Three serotypes
• Type 1,2
• Type1,3
• Type 1,2,3

3
pathogenesis

• Non invasive infection of respiratory mucosa
• Ciliated epithelium of bronchi , trachea
• Human is the only natural host
• IP 1 2 weeks
• Tracheal cytotoxin ( TC )
• Pertussis toxin (PT)
• Lymphocytosis
• Filamentous haemagglutnin (FHA)

4
clinical

• Catarrhal phase ( preventable )-most infectious
• Paroxysmal phase ( sever cough)
• Convalescent phase
• Atypical cases
• Complications
• Bronchopneumonia
• Secondary infection
• Lung collapse
• Anoxia , convulsions

5
EPIDEMIOLOGY

• SOURSE
• Patients ( droplets ) child or adults
• Atypical cases
• Cmunicable
• Epidemics
• Antibiotics reduce transmission
• Incidence and mortality
• All ages
• Cause of death ( lt 2 years , infants )

6
Immunity

• One attack confers long lasting immunity
• (herd immunity)
• Infection with different serotype
• Passive protection from mother is incomplete
• 3 injections of vaccine effective active
  immunity

7
Diagnosis

• Clinical
• lymphocytosis
• Laboratory
• Nasopharynx (postnasal swab )
• Pernasal swab
• Selective media
• Slid agglutinations ( antiserum)

8
Treatment

• No effect in well established infection
• Erythromycin
• Reduce severity if given before paroxysmal phase
• For 14- days
• Reduces transmission
• Prophylaxis of contacts

9
Control

• Vaccination is safe - gt 90 effective
• Whole bacterial cell ( killed) deep IM inj.
• Contain 3 agglutinogens
• 3 doses
• SE neurological sequelae , crying , fever
• Acellular pertussis vaccine
• PT , FHA agglutinogens